| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| - | vitro+vivo, | Melanoma, | NA | - | Case Report, | Melanoma, | NA |
| - | Human, | MS, | NA | - | NA, | IBD, | NA |
| 6803- | EA, | Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial |
| - | Trial, | IBD, | NA |
| 6802- | EA, | Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate |
| - | Human, | Pca, | NA |
| 6801- | EA, | A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury |
| - | vitro+vivo, | BC, | 4T1 |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1617- | EA, | CUR, | The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin |
| - | in-vitro, | Nor, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 6614- | Ech, | Echinacea: a Miracle Herb against Aging and Cancer? Evidence In vivo in Mice |
| - | in-vivo, | Var, | NA |
| 6612- | Ech, | Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial |
| - | Trial, | Nor, | NA |
| 6604- | Ech, | Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion |
| - | Human, | Nor, | NA |
| 6609- | Ech, | Cic, | Echinacea purpurea Extract Enhances Natural Killer Cell Activity In Vivo by Upregulating MHC II and Th1-type CD4+ T Cell Responses |
| - | in-vivo, | Nor, | NA |
| 6610- | Ech, | Cic, | A standardized extract of Echinacea purpurea containing higher chicoric acid content enhances immune function in murine macrophages and cyclophosphamide-induced immunosuppression mice |
| - | in-vivo, | Nor, | NA |
| 6618- | Ech, | Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach |
| - | Analysis, | BC, | NA |
| 6617- | Ech, | Echinacea Angustifolia DC Extract Induces Apoptosis and Cell Cycle Arrest and Synergizes with Paclitaxel in the MDA-MB-231 and MCF-7 Human Breast Cancer Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 7191- | EGb 761, | Pharmacokinetic drug interactions involving Ginkgo biloba |
| - | NA, | Nor, | NA |
| 7194- | EGb 761, | Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells |
| - | in-vitro, | Oral, | NA |
| 7203- | EGb 761, | Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials |
| - | Review, | AD, | NA |
| 7200- | EGb 761, | PCA, | Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference |
| 7196- | EGb 761, | Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 7225- | EGb 761, | Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial |
| - | Trial, | AD, | NA |
| 7230- | EGb 761, | Ginkgo biloba extract (EGb 761) promotes peripheral nerve regeneration and neovascularization after acellular nerve allografts in a rat model |
| - | in-vivo, | Nor, | NA |
| 7229- | EGb 761, | Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia |
| - | Review, | AD, | NA |
| 7228- | EGb 761, | Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders |
| - | Review, | AD, | NA |
| 7222- | EGb 761, | Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use |
| - | Review, | AD, | NA |
| 7220- | EGb 761, | Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric Cancer |
| - | vitro+vivo, | GC, | SGC-7901 |
| - | Trial, | Nor, | NA |
| 7236- | EGb 761, | Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia |
| - | in-vivo, | Stroke, | NA |
| 3721- | EGb 761, | Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice |
| - | Review, | AD, | NA |
| 3245- | EGCG, | (−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway |
| - | in-vitro, | Nor, | PC12 |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 6781- | EGCG, | Scientific opinion on the safety of green tea catechins |
| - | Review, | Nor, | NA |
| 6780- | EGCG, | The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review |
| - | Review, | AD, | NA |
| 6779- | EGCG, | Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review |
| - | Review, | AD, | NA |
| 6782- | EGCG, | Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability |
| - | Human, | Nor, | NA |
| 6789- | EGCG, | Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? |
| - | Review, | Var, | NA |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| 2501- | EGCG, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 6049- | EGCG, | SeNPs, | Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity |
| - | Study, | AD, | PC12 |
| 1975- | EGCG, | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
| - | in-vitro, | Cerv, | HeLa |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 6830- | EMD, | Anticancer activity of emodin is associated with downregulation of CD155 |
| - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | BC, | E0771 | - | in-vitro, | BC, | 4T1 |
| 5227- | EMD, | Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy |
| - | vitro+vivo, | Nor, | NA |
| 6110- | EP, | Leukemic cell intracellular responses to nanosecond electric fields |
| - | in-vitro, | AML, | NA |
| 5525- | EP, | Cell responses without receptors and ligands, using nanosecond pulsed electric fields (nsPEFs) |
| - | Review, | Var, | NA |
| 5527- | EP, | Nanosecond pulsed electric field (nsPEF) application effects on human cells: intracellular membrane disruption and apoptosis induction |
| - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid